25.43
-0.44 (-1.70%)
| Previous Close | 25.87 |
| Open | 25.79 |
| Volume | 2,127,736 |
| Avg. Volume (3M) | 2,149,106 |
| Market Cap | 2,805,826,304 |
| Price / Sales | 195.72 |
| Price / Book | 9.98 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Operating Margin (TTM) | -1,525.50% |
| Diluted EPS (TTM) | -3.01 |
| Quarterly Revenue Growth (YOY) | 184.40% |
| Total Debt/Equity (MRQ) | 1.55% |
| Current Ratio (MRQ) | 10.49 |
| Operating Cash Flow (TTM) | -152.68 M |
| Levered Free Cash Flow (TTM) | -117.16 M |
| Return on Assets (TTM) | -33.54% |
| Return on Equity (TTM) | -69.21% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Immunome, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.13 |
|
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 11.48% |
| % Held by Institutions | 83.28% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ecor1 Capital, Llc | 30 Sep 2025 | 4,079,415 |
| Jefferies Financial Group Inc. | 30 Sep 2025 | 2,100,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 40.00 (Evercore ISI Group, 57.30%) | Buy |
| Median | 34.00 (33.70%) | |
| Low | 31.00 (Wedbush, 21.90%) | Buy |
| Average | 34.50 (35.67%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 21.62 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 15 Jan 2026 | 31.00 (21.90%) | Buy | 22.85 |
| Evercore ISI Group | 16 Dec 2025 | 40.00 (57.29%) | Buy | 23.48 |
| Guggenheim | 16 Dec 2025 | 35.00 (37.63%) | Buy | 23.48 |
| Lake Street | 16 Dec 2025 | 32.00 (25.84%) | Buy | 23.48 |
| Truist Securities | 01 Dec 2025 | 36.00 (41.57%) | Buy | 18.32 |
| Stephens & Co. | 17 Nov 2025 | 33.00 (29.77%) | Buy | 18.13 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |